ArticleEndocrine2021
Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review.BMC endocrine disorders · 2022Pooled it
- [Primary aldosteronism as an independent factor of kidney damage. Potential therapeutic strategies and research prospects].Problemy endokrinologii · 2026Review
- Review
- Blood pressure patterns and cardio-renal complications in primary aldosteronism compared with essential hypertension in a tunisian population.Journal of human hypertension · 2026Article
- Aldosterone fuels the progression of cardiovascular-kidney -metabolic syndrome: focus on primary aldosteronism spectrum.Endocrine · 2026Review
- Multiparametric diffusion-weighted MRI for renal microstructural assessment in patients with primary aldosteronism at varying direct renin concentrations.Abdominal radiology (New York) · 2026Article
- Interplay Between the Mineralocorticoid System, Inflammation, Hypertension, and Kidney Disease.Kidney360 · 2025Review
- Noninvasive evaluation of renal oxygenation by blood oxygenation level-dependent magnetic resonance imaging in patients with primary aldosteronism.Scientific reports · 2025Article
- Clinical value of sublingual microcirculatory dysfunction for screening for primary aldosteronism in hypertensive patients.Frontiers in endocrinology · 2025Article
- Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests.Endocrine · 2024Article
- Review
- Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?Endocrine · 2024Review
- Association of Dip in eGFR With Clinical Outcomes in Unilateral Primary Aldosteronism Patients After Adrenalectomy.The Journal of clinical endocrinology and metabolism · 2024Article
- Kidney function predicts new-onset cardiorenal events and mortality in primary aldosteronism: approach of the 2021 race-free eGFR equation.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Observational
- Chronological outcomes of renal function after adrenalectomy in patients with primary aldosteronism across age groups.Frontiers in endocrinology · 2024Article
- Article
- The potential of a new nomogram for the diagnosis of primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- The Effect of Aldosterone on Cardiorenal and Metabolic Systems.International journal of molecular sciences · 2023Review
- Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.Journal of the American Heart Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the differences in the prevalence, risk, and grade of control of different cardiometabolic comorbidities in patients with primary aldosteronism (PA) and essential hypertension (EH) matched by age, sex, and blood pressure levels at diagnosis.
methodsCase-control study of a secondary base (PA patients in follow-up in a tertiary hospital between 2018 and 2020). Controls were patients with non-functioning adrenal incidentalomas and EH, matched by age, sex, and baseline diastolic blood pressure (DBP) and systolic blood pressure (SBP).
resultsFifty patients with PA and 50 controls were enrolled in the study. At diagnosis, PA patients had a higher prevalence of chronic kidney disease (CKD) than controls (18.4% vs. 2.1%, P = 0.008). No differences were detected in the prevalence of other cardiometabolic comorbidities nor in their degree of control (P > 0.05). All patients received antihypertensive medical treatment and 10 PA patients underwent unilateral laparoscopic adrenalectomy. After a median follow-up of 31.9 [IQR = 1.0-254.8] months, PA patients presented a greater degree of declination of kidney function than controls (average decrease in glomerular filtration rate (MDRD-4) -17.6 ± 3.1 vs. -2.8 ± 1.8 ml/min/1.73 m
conclusionsPA patients have a higher prevalence of CKD at the time of diagnosis when compared to EH matched by age, sex, and blood pressure levels. Furthermore, the risk of kidney function impairment throughout the follow-up is significantly greater in PA patients and is independent of the degree of blood pressure control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.